Vitas Pharma - About the company
Vitas Pharma is a deadpooled company based in Hyderabad (India), founded in 2010 by Rajinder Kumar and Radha Rangarajan. It operates as an Indian, preclinical stage biopharma developing small molecule therapeutics for MDR bacterial infections (ESKAPE pathogens). Vitas Pharma has raised $484K in funding, with last known valuation of $*****. The company has 223 active competitors, including 78 funded and 40 that have exited. Its top competitors include companies like Spero Therapeutics, LimmaTech Biologics and Bioversys.
Company Details
Vitas Pharma is an Indian, preclinical stage biopharma developing small molecule therapeutics for MDR bacterial infections. The company focuses on infections that are usually acquired in hospitals. Its products are developed on its proprietary platform, called Tackling Antimicrobial Resistance through Novel Scaffolds (TARNS). It has a novel pipeline of molecules to treat infections caused by multidrug-resistant bacteria. Its lead product VT-02 for MRSA is in toxicology studies. The other candidates are VT-01 for gram-negative infections and VT-03 for Acinetobacter infections. The company is also developing companion diagnostics for the detection of Carbapenem resistance (Lab Testing stage) and MRSA detection (feasibility stage).
- Website
- vitaspharma.com
- Email ID
- *****@vitaspharma.com
- Registered Address
- PLOT NO.12, APARNA ORCHIDS MADHAPUR, HYDERABAD, Telangana, India, 500084
Key Metrics
Founded Year
2010
Location
Hyderabad, India
Stage
Deadpooled
Total Funding
$484K in 1 round
Latest Funding Round
Last Known Valuation
$***** as on Jan 17, 2015
Investors
Ranked
87th among 223 active competitors
Annual Revenue
0 - ₹10 Cr as on Mar 31, 2020
Employee Count
6 as on Jul 01, 2024
Similar Companies
Legal entities associated with Vitas Pharma
Vitas Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
VITAS PHARMA RESEARCH PRIVATE LIMITED CIN: U73100TG2010PTC068813 , India, Strike off | Jun 07, 2010 | 0 - ₹10 Cr (As on Mar 31, 2020) | - |
Sign up to download Vitas Pharma's company profile
Vitas Pharma's funding and investors
Vitas Pharma has raised a total funding of $484K over 1 round. Its latest funding round was a Seed round on Jan 17, 2015 for $*****. 43 investors participated in its latest round. Vitas Pharma has 12 institutional investors and 35 angel investors.
Here is the list of recent funding rounds of Vitas Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 17, 2015 | 1815918 | Seed | 2213599 | 5041788 | 3397859 | 1707479 |
View details of Vitas Pharma's funding rounds and investors
Vitas Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Vitas Pharma are Rajinder Kumar and Radha Rangarajan.
Here are the details of Vitas Pharma's key team members:
- Rajinder Kumar: Co-Founder & CMO of Vitas Pharma. They are also an angel investor in 1 startup and serve on the boards of 2 companies.
- Radha Rangarajan: Founder & CEO of Vitas Pharma. They serve on the board of 1 company.
Vitas Pharma's Board of Directors
Vitas Pharma's board has 2 active members. Rajinder Kumar and Radha Rangarajan are part of team.Here is the list of Vitas Pharma's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 16y 5m | |
jabvqyc | Team | - | Past | 7y 1m |
View details of Vitas Pharma's Founder profiles and Board Members
Vitas Pharma's employee count trend
Vitas Pharma has 6 employees as of Jul 24. Here is Vitas Pharma's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Vitas Pharma's Competitors and alternates
Top competitors of Vitas Pharma include Spero Therapeutics, LimmaTech Biologics and Bioversys. Here is the list of Top 10 competitors of Vitas Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Spero Therapeutics 2013, Cambridge (United States), Public | Developer of therapeutics for drug-resistant bacterial infections | $115M | 67/100 | |
2nd | LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired | Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques | $40M | 65/100 | |
3rd | Bioversys 2008, Basel (Switzerland), Public | Developer of therapeutics for Antimicrobial Resistance | $62.5M | 63/100 | |
4th | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 60/100 | |
5th | Pattern Bioscience 2016, Austin (United States), Series C | Provider of multiple diagnostics platforms for infectious diseases | $105M | 59/100 | |
6th | Developer of multi-targeted antibacterial compounds | $7.51M | 59/100 | ||
7th | Everest Medicines 2017, New York City (United States), Public | Developer of drugs for the treatment of cancer | $313M | 58/100 | |
8th | Clarametyx 2019, Columbus (United States), Series A | Developer of biologic therapies and vaccines for biofilm-related chronic bacterial infections | $33M | 57/100 | |
9th | Omnix Medical 2015, Jerusalem (Israel), Series C | Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections | $25M | 57/100 | |
10th | CARB-X 2016, Boston (United States), Funding Raised | Developer of antibiotics against-drug resistant bacteria | - | 57/100 | |
87th | Vitas Pharma 2010, Hyderabad (India), Deadpooled | Indian, preclinical stage biopharma developing small molecule therapeutics for MDR bacterial infections (ESKAPE pathogens) | $484K | 35/100 |
Looking for more details on Vitas Pharma's competitors? Click here to see the top ones
Financials of Vitas Pharma
VITAS PHARMA RESEARCH PRIVATE LIMITED, the legal entity associated with Vitas Pharma, generated less than ₹10 Cr in revenue for the financial year ending on Mar 31, 2020. The revenue of VITAS PHARMA RESEARCH PRIVATE LIMITED has a compounded annual growth rate (CAGR) of 32% in the last 1 year.
Financial Statement Summary
Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|---|---|
Income Statement | |||||
Revenue | 4996 | 7773 | 9666 | 3337 | 7775 |
Total Sales | 3791 | 3365 | 8568 | 5779 | 3326 |
Total Expenses | 5999 | 8660 | 3320 | 4841 | 6964 |
Operating Expenses | 9338 | 4657 | 4401 | 4775 | 4996 |
Employee Expenses | 9728 | 5958 | 4148 | 6680 | 5798 |
Operating Income (EBIT) | 2203 | 2126 | 5693 | 9979 | 8828 |
Interest Expenses | 8668 | 3488 | 5115 | 7731 | 5271 |
Expenses from other activities | 4821 | 1552 | 6063 | 2465 | 5762 |
EBITDA | 3654 | 5638 | 1741 | 9997 | 1621 |
Taxes | 5703 | 9913 | 4619 | 1499 | 5624 |
Net Profit | 6429 | 1865 | 1542 | 8250 | 8147 |
Balance Sheet | |||||
Assets | 5145 | 1765 | 4145 | 2014 | 3228 |
Accounts Receivables | 8697 | 1982 | 5262 | 6852 | 3474 |
Inventory | 4236 | 8113 | 4795 | 4126 | 1251 |
Liabilities | 5553 | 6202 | 3696 | 8847 | 1239 |
Total Debt | 7553 | 2667 | 5719 | 1441 | 2588 |
Accounts Payable | 7763 | 9309 | 9524 | 5222 | 9875 |
Equities | 2660 | 9046 | 6241 | 2726 | 1341 |
Detailed Financials (Income Statement, Balance Sheet, Cashflow Statement)
Vitas Pharma's Investments and acquisitions
Vitas Pharma has made no investments or acquisitions yet.
Reports related to Vitas Pharma
Here is the latest report on Vitas Pharma's sector:
Are you a Founder ?
FAQs about Vitas Pharma
Explore our recently published companies
- Seededge Solutions - Pune based, Unfunded company
- Secuarden AI - Melbourne based, 2026 founded, Unfunded company
- Secretair AI - France based, 2025 founded, Unfunded company
- Second Loop AI - Unfunded company
- Seawin AI - Unfunded company
- Seamless IT AI - United States based, Unfunded company